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Antibody diversifi  cation in B cells is an im-
portant component of immune responses 
against foreign antigens. Ig gene diversity is 
fi  rst created by V(D)J recombination, which 
is responsible for assembling the primary func-
tional repertoire, and this is followed by gene 
conversion (GCV) and somatic hypermutation 
(SHM), processes that further increase sequence 
diversity at the variable regions of Ig genes. 
GCV is achieved by copying patches of se-
quences from sequence donors into the variable 
regions, whereas SHM events are nontemplated 
and exist mainly as single point mutations. Both 
GCV and SHM are dependent on activation-
induced cytidine deaminase (AID) (1–4), which 
is thought to initiate the reactions by deami-
nating deoxycytosine residues in Ig genes. The 
uracils thereby generated are then processed by 
uracil DNA glycosylase and mismatch repair 
proteins and channeled into homology-based 
repair for GCV or by error-prone repair for 
SHM (5–8).
GCV and SHM are thought to be restricted 
largely to Ig genes. The molecular basis of this 
restriction has been the subject of intensive in-
vestigation, with cis-acting DNA elements in 
Ig genes being the prime candidates for provid-
ing targeting specifi  city. Numerous studies in-
dicate a tight link between AID-dependent 
diversifi   cation of Ig genes and transcription. 
The region that undergoes SHM is 1–2 kb 
downstream of Ig transcription start sites, which 
spans the variable region exon (9–11). Studies 
using knockout mice and transfected cell lines 
have shown that no SHM occurs in the ab-
sence of an active promoter (12, 13). Additional 
studies with transgenic mice demonstrated that 
promoter location dictates the region of SHM, 
as a newly inserted promoter creates a new 
window of mutation, and altered positioning 
of the promoter shifts the mutating region 
(10, 14). Nonetheless, the endogenous Ig 
  promoters are thought not to be necessary be-
cause several non-Ig promoters in diff  erent 
model systems could support SHM when used 
to replace the Ig promoter (13, 15, 16). Similarly, 
studies of transgenes in mice and heterologous 
expression vectors in hypermutating B cell 
lines indicated that the Ig variable region 
exon itself is not required for SHM (17–19). 
Importantly, experiments performed in cell 
lines have indicated a positive correlation 
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  between transcription levels and SHM frequencies (12, 19). 
These results have led to the conclusion that rather than act-
ing as targeting elements, Ig promoters simply mediate the 
transcription essential for SHM. However, very few experi-
ments have been performed to examine the role of the pro-
moter in the context of endogenous Ig genes (13, 15).
Another focus of interest has been Ig gene   enhancers. 
Studies using mouse Ig light chain κ (Igκ) transgenes showed 
that deletion of the intronic or 3′ Igκ enhancer strongly 
reduced SHM, suggesting an important role of enhanc-
ers in SHM (16, 20, 21). However, when the mouse Igκ 
intronic enhancer, 3′κ enhancer, or Ig heavy chain (IgH) 
intronic enhancer were deleted in their endogenous context, 
SHM was not substantially aff  ected (22–24). The discre-
pancy could refl  ect redundant functions provided by other 
cis-acting elements in the endogenous loci or limitations of 
transgenic studies related to low mutation rates and posi-
tion eff  ects coming from diff  erent integration sites. For its 
part, deletion of endogenous enhancers from the   germline 
has the potential limitation that epigenetic alterations or 
selection might take place to compensate for the lack of 
the enhancer during earlier stages of B cell development. 
Recently, several reports have indicated positive eff  ects of 
E2A proteins on AID-dependent diversifi  cation processes 
(25–27). As E2A binding sites are found in Ig enhancers, it 
is possible that the enhancers play an important role in Ig 
gene sequence diversifi  cation. In investigating such a role, 
it is important to distinguish a putative targeting activity of 
enhancers from their ability to facilitate transcription, be-
cause stronger transcription can itself contribute to higher 
levels of SHM.
To investigate the molecular mechanisms of targeting in 
Ig sequence diversifi  cation, we analyzed two regions in the 
Ig light chain (IgL) locus of DT40 cells, the promoter and 
the enhancer. DT40 is a chicken B cell line that undergoes 
continuous GCV and SHM in its IgL and IgH loci, and 
it performs homologous recombination effi   ciently, thereby 
enabling manipulation of DNA elements in their endog-
enous context (28–30). Deletion of the single known IgL 
enhancer element while maintaining high levels of transcrip-
tion showed that the enhancer was not essential for GCV/
SHM. Analysis of the promoter region revealed that an ac-
tive promoter is crucial for GCV/SHM and that the endog-
enous promoter could be functionally replaced by a strong 
heterologous promoter. Surprisingly, we found that the 
human elongation factor 1-α (EF1-α) promoter supported 
GCV/SHM poorly, even though it drove transcription 
effi   ciently. This is the fi  rst time a strong non-Ig promoter 
has been shown to have a substantial defect in supporting Ig 
sequence diversifi  cation in an endogenous Ig locus, which 
argues that the function of the promoter in GCV/SHM 
must extend beyond simply driving transcription. Overall, 
our results indicate that cis-acting elements contribute to 
the targeting effi   ciency of Ig gene diversifi  cation and that 
high-level transcription in an Ig locus is not suffi   cient for 
effi   cient GCV/SHM.
RESULTS
Generation of IgL promoter-substituted clones
There is a well-established link between transcription and 
SHM in mammalian B cells, but this issue has not been inves-
tigated for GCV/SHM in chicken B cells. To address this, 
we replaced the endogenous IgL promoter in DT40 cells 
with three heterologous promoters: the bacteriophage T7 
promoter, which should not be able to initiate transcription 
in eukaryotic cells, and two strong Pol II promoters, the 
chicken β-actin and the human EF1-α promoter. The IgL 
promoter region that was replaced extended from 206 bp 
upstream to 6 bp downstream of the transcription start site 
and contained the octamer binding motif and TATA-box es-
sential for IgL promoter function (31, 32). The CL18 clone 
of DT40 cells was transfected with targeting constructs con-
taining diff  erent promoters and seeded out at limiting dilu-
tion, and stable transfectants were identifi  ed after 6–8 d (see 
Materials and methods; Fig. 1 A) (30). Southern blots were 
performed to distinguish clones in which targeted integration 
of the constructs into the rearranged IgL allele had occurred 
(targeted integrants) from those in which random integration 
into other parts of the genome had taken place (random 
  integrants). At least two independent targeted integrants were 
  selected for subsequent analysis and treated with recombinant 
Cre protein to remove the puromycin selection cassette in-
serted upstream of the promoter as a result of targeted inte-
gration (Fig. 1 A). Cre-treated cells were single-cell seeded 
again, and clones that grew out were verifi  ed for successful 
Cre-mediated deletion by Southern blots (Fig. 1 B). Overall, 
the targeting effi   ciency of our promoter-swapping constructs 
was  45%, and the effi   ciency of Cre-mediated deletion was 
 90% (not depicted).
IgL expression driven by the new promoters was mea-
sured by Northern blots. As expected, no transcription was 
detected from the T7 promoter (T7 cells), although removal 
of the normal V promoter appeared to activate cryptic pro-
moters that generated low-level transcription initiating at the 
3′ end of the V segment (not depicted). Conversely, both 
β-actin and EF1-α promoter-substituted cells (βA and EF 
cells, respectively) expressed the IgL locus at levels higher than 
the endogenous promoter (Fig. 1 C and Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20061835/DC1).
The 𝗃-actin promoter supports GCV/SHM
Two established assays were used to measure levels of GCV/
SHM. First, direct sequencing was performed on cloned 
PCR products of the 500-bp region downstream of the IgL 
transcription start site from genomic DNA of cells cultured 
for 28 d. Second, IgM reversion assays were performed, tak-
ing advantage of a frameshift mutation in the IgL variable 
region of CL18-derivative clones that can be corrected by 
certain GCV events to generate IgM+ cells (30). As only 
a few pseudogenes are able to correct the frameshift muta-
tion and each culture begins as a single cell, the percent-
ages of IgM+ cells in diff  erent clones of the same genotype 
exhibited considerable fl  uctuation. Consequently, multiple JEM VOL. 203, December 25, 2006  2921
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clones of a given genotype were analyzed, and the median 
of each group was used for comparison. In addition, suc-
cessive rounds of subcloning were performed to ensure that 
GCV/SHM phenotypes were stable (cells that have under-
gone diff  erent numbers of subclonings will be referred to 
as belonging to diff  erent generations). Subcloning was per-
formed when cells had been grown for 3 wk since they were 
last subcloned. Cells were maintained for a total of 4 wk 
for each round of subcloning, during which IgM reversion 
frequencies were assessed; at the end of this time, DNA was 
prepared for sequencing.
After 4 wk of culture, a signifi  cant percentage of βA cells 
had become surface IgM+ (sIgM+) compared with AID−/− 
controls (combined dataset from three generations of βA 
cells; P ≤ 0.0001; Fig. 2 A) (2). When the IgM reversion re-
sults were separated based on the number of subclonings the 
Figure 1.  Generation and analysis of promoter-substituted cells. 
(A) Schematic diagram of steps involved in replacing the endogenous IgL 
promoter with heterologous promoters. Relevant components of the IgL locus 
are indicated as rectangles, with the IgL promoter in gray, and the start site 
of transcription is indicated by the arrow. Only the eight most proximal ψV 
elements are shown. The puromycin resistance cassette (puroR; rectangle) 
is fl  anked by loxP sites (triangles) and the heterologous promoter (hexagon) 
is indicated. Relevant restriction enzyme sites and the constant region 
probe (solid bar) used in Southern and Northern blots are indicated. 
(B, top) A representative Southern blot for identifying targeted integrants 
(HindIII/SpeI digest) is shown; the higher molecular mass band in each lane 
derives from the unrearranged IgL allele (unrrng), whereas the lower band 
is derived from the rearranged allele (rrng; lanes 1 and 2) or the targeted 
rearranged allele (T; lanes 3 and 4). REC, two different targeted recombi-
nants; WT, two randomly integrated clones that show wild-type band 
patterns. (B, bottom) A representative Southern blot for verifi  cation of 
successful Cre-mediated deletion (BglII/SpeI digest). Before Cre deletion, 
the rearranged IgL allele (T; lane 4) generates a larger fragment than the 
unrearranged allele (unrrng; lane 4); upon puro cassette removal, the band 
derived from the rearranged IgL allele becomes smaller in size than that of 
the unrearranged allele (D; lanes 1–3). (C) Quantitation of steady-state IgL 
transcript levels in various promoter-substituted or enhancer-deleted cell 
lines as assessed by Northern blots (a representative blot is shown in Fig. S1). 
Blots were hybridized with the IgL constant region probe and the GAPDH 
probe as an internal control and quantitated, and the IgL/GAPDH ratio 
was calculated. The ratio for wild-type CL18 cells was arbitrarily set to 1, 
and all other values are expressed relative to this. The height of each bar 
represents the average of two to four determinations with the standard 
deviation, as indicated by the error bars. WT, wild-type CL18 cells; βA, 
cells in which the IgL promoter was replaced with the β-actin promoter; 
L, cells in which the IgL promoter was replaced with itself; EF, cells in which 
the IgL promoter was replaced with the EF1-α promoter; EF-L, cells that 
have gone through two successive rounds of targeted replacement of the 
IgL promoter (the fi  rst to replace the IgL promoter with the EF1-α promoter 
and the second to revert the EF1-α promoter back to the IgL promoter); 
∆E, cells in which the IgL enhancer was deleted; βA∆E, cells in which 
the IgL enhancer was deleted with the β-actin promoter driving IgL 
  transcription; E, cells in which the IgL enhancer was replaced by itself.2922  IG PROMOTER AND ENHANCER IN GCV/SHM | Yang et al.
cells had gone through, no diff  erence was found between 
diff  erent generations, indicating that the GCV/SHM pheno-
type was stable over time (Fig. 2 B). Moreover, weekly 
  examination of the cells showed that the percentages of IgM+ 
cells increased over time (Fig. 2 C shows median values; 
data for all clones are shown in Fig. S2 B, available at 
http://www.jem.org/cgi/content/full/jem.20061835/DC1), 
confi  rming the ability of the β-actin promoter to support 
GCV in the IgL locus. Although we noted a slowing of accu-
mulation of sIgM+ cells in the βA cell cultures between days 
21 and 28 as compared with between days 14 and 21, the data 
from successive subclonings of these cells indicate no loss of 
GCV/SHM activity with the age of the cells (Fig. 2 B).
Sequence analysis corroborated the fi  ndings from the IgM 
reversion assays. At day 28, we found 43 total events (long-
track GCV, templated mutations, and nontemplated events 
combined) out of 274 sequences analyzed for the βA cells 
(combined dataset over three generations; Table I). In com-
parison, T7 cells generated no diversifi  cation events in the 
138 sequences obtained (βA vs. T7 cells; P ≤ 0.0001). These 
results indicate that GCV/SHM in DT40 cells relies on a 
functional promoter and that the endogenous promoter is 
not essential.
Manipulation of the IgL locus around the promoter 
interferes with optimal GCV/SHM
Although the βA cells were able to perform GCV/SHM, we 
noticed that they did so only half as effi   ciently as the wild-
type CL18 cells (WT cells; Fig. 2, A–C; and Table I). This 
was not an artifact resulting from transfection, subcloning, 
selection, or phenotypic fl  uctuation of the cells, as random-
integrant clones (unaltered in the IgL locus) derived from 
transfections of diff   erent targeting constructs performed 
GCV/SHM in the endogenous IgL locus at levels comparable 
to those of untransfected CL18 cells (not depicted). Sequencing 
and IgM reversion results from random integrants and un-
transfected CL18 cells have thus been pooled together as the 
wild-type dataset.
We therefore considered the possibility that the  promoter-
exchange scheme altered the IgL locus in a manner that 
  impaired GCV/SHM. To address this, a targeting vector 
similar to that used to generate βA and EF cells was created 
to replace the IgL promoter with an exact copy of itself. We 
expected that cells arising from targeted integration of this 
construct (L cells, derived from one parental clone) would be 
identical to WT cells, except that they would have under-
gone the same recombination events in the IgL locus as other 
promoter-substituted cells and retained a loxP site upstream 
of the promoter. Northern blots demonstrated that IgL ex-
pression was not aff  ected by this synonymous substitution 
(compare WT with L; Fig. 1 C).
Interestingly, L cells exhibited a twofold reduction in 
IgM reversion relative to WT cells (P = 0.0016; Fig. 2 A and 
Fig. S2 C), indicating that the promoter replacement scheme 
reduced the effi   ciency of GCV/SHM. Furthermore, com-
parison of βA and L cells (Fig. 2 A) indicates that the β-actin 
promoter supports the same frequency of GCV/SHM as the 
normal IgL promoter, and that the reduction in GCV/SHM 
seen in βA cells relative to WT cells was most likely caused 
by locus manipulations (see Discussion).
The EF1-𝗂 promoter is defective in supporting GCV/SHM
To our surprise, the EF1-α promoter yielded results quite 
diff  erent from those of the β-actin promoter. EF cells gener-
ated very few sIgM+ cells over the course of 28 d (three- to 
fourfold less than L cells; Fig. 2 A). This was a stable pheno-
type, observed in three successive generations of EF cells 
(Fig. 2 B). When the medians of the percentages of IgM+ 
Figure 2.  IgM reversion assay of various promoter-substituted 
and enhancer-deleted cell lines. (A) The percentages of surface IgM+ cells 
at day 28 for the cell types indicated along the x axis; cells of all genera-
tions are included. Each dot represents a subclone of the indicated cell 
type, and the black bar marks the median of each group. The number in 
parentheses below the name of each cell type is the total number of 
  subclones analyzed for that cell type. (B) The percentages of surface IgM+ 
cells in βA and EF cells at day 28, separated according to the different 
generations of subclones analyzed. The black bar marks the median of 
each group. (C) Time course analysis of IgM+ cell accumulation. Each data 
point represents the median of all clones of the given genotype at the 
indicated time point. Cell lines are abbreviated as in Fig. 1.JEM VOL. 203, December 25, 2006  2923
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cells of clones at days 14, 21, and 28 were plotted, minimal 
increases were observed with increased culture times (Fig. 
2 C and Fig. S2 D). Sequencing results pooled from EF cell 
clones from diff  erent generations confi  rmed that their GCV/
SHM activity was signifi  cantly reduced compared with WT 
and βA cells (P ≤ 0.0001 and P = 0.024, respectively; Table I). 
Though the defect in GCV/SHM of EF cells as assayed by 
sequencing analysis is less pronounced than by IgM reversion 
assay, the latter is more quantitative, as it monitors hundreds 
of thousands of cells, whereas the sequencing assay sampled 
only a couple of hundred alleles for each cell type.
As the EF1-α promoter was able to drive higher levels 
of IgL transcription than the endogenous IgL promoter (Fig. 
1 C), we were intrigued by its inability to support effi   cient 
GCV/SHM. To ascertain whether EF clones might have 
some unrelated defect that could explain the IgL GCV/SHM 
results, we fi  rst sequenced the IgH locus in the EF cells. 
Comparable levels of IgH GCV/SHM were found in EF and 
WT cells (Table II); therefore, the GCV/SHM defect was 
specifi  c to the IgL locus. We next tested whether the IgL 
  locus itself had been inactivated for GCV/SHM by reinserting 
the endogenous IgL promoter into the rearranged IgL locus 
of EF cells (with attendant deletion of the EF1-α promoter) 
to generate EF-L cells. As expected, levels of IgL expression 
in EF-L cells were similar to those seen in WT and L cells 
and lower than in EF cells (Fig. 1 C). Analysis of IgM rever-
sion in EF-L cells showed levels of IgM reversion fourfold 
higher than those in EF cells (P = 0.0006; Fig. 2 A and Table I); 
sequence analysis also confi  rmed the GCV/SHM frequencies 
in EF-L cells to be higher than those in EF cells (Table I). 
Our ability to rescue the GCV/SHM defect in the IgL   locus 
of EF cells by reinsertion of the endogenous promoter 
strongly suggests that the EF cell defect was specifi  c to the 
EF1-α promoter and was not caused by other factors or 
  alterations. In addition, EF-L cells were only able to perform 
GCV/SHM at about half the effi   ciency of wild-type cells 
(Fig. 2 A and Table I), consistent with observations in L cells 
and demonstrating again the eff  ect of the targeting scheme 
on GCV/SHM.
Deletion of the IgL enhancer
The only known transcriptional enhancer in the chicken IgL 
locus was identifi  ed in a transgenic mouse study as a 1.7-kb 
fragment 2 kb downstream of the constant region (33). 
Transient transfection assays were subsequently used to local-
ize the enhancer to a  500-bp region (32). To test the involve-
ment of the enhancer in IgL GCV/SHM, this region was 
deleted in CL18 and βA cells (see Materials and methods; 
Fig. 3 A). Deletion of the IgL enhancer in the βA cells was of 
particular interest, because we anticipated that transcription 
driven by the β-actin promoter would be minimally depen-
dent on the enhancer, thereby allowing us to identify poten-
tial roles of the enhancer in GCV/SHM beyond facilitation 
of transcription. Stable transfectants of the enhancer deletion 
construct into WT and βA cells were screened by Southern 
blots to identify targeted integrants (Fig. 3 B), and for each 
at least two independent clones were selected for further 
characterization. As a control, a cell line in which the enhancer 
was retargeted into the rearranged IgL allele of CL18 cells 
was also generated (E cells); the only genotypic diff  erence 
between E cells and CL18 cells should be an 80-bp fragment 
Table I.  Sequence diversifi  cation in the IgL locus
Cell typea Total 
eventsb
Total 
sequences
Frequency 
(×10−4 events/bp)c
Event typesd
Long-track 
GCV
Templated 
mutations
Nontemplated 
eventse
WT 86 276 6.2 31 32 14 (23)
T7 0 138 0 0 0 0 (0)
βA 43 274 3.1 18 13 12 (12)
EF 25 396 1.3 10 6 6 (8)
EF-L 15 114 2.6 5 8 2 (2)
∆E 11 174 1.3 5 3 3 (3)
βA∆E 33 208 3.2 11 13 6 (8)
aWT, DT40 CL18 cells; T7, T7 promoter knock-in cells; βA, β-actin promoter knock-in cells; EF, EF1-α promoter knock-in cells; EF-L, IgL promoter placed back into the IgL locus 
of EF1-α promoter knock-in cells; ∆E, enhancer-deleted cells; βA∆E, enhancer deletion with β-actin promoter driving transcription.
bIncludes all types of sequence variations (long-track GCV, templated mutations, and nontemplated events, categorized as described in Materials and methods).
cLength of sequences = 500 bp.
dSequence variations are classifi  ed as detailed in Materials and methods.
eThe number indicates nontemplated events found in the VJ region; the number in parentheses includes the entire sequenced region, which included parts of the leader 
and J-C intron.
Table II.  Sequence diversifi  cation in the IgH locus
Cell typea Diversifi  ed 
sequencesb
Total 
sequences
% diversifi  ed 
sequences
WT 14 65 22
EF 24 114 21
AID−/− 0 38 0
aWT, DT40 CL18 cells; EF, EF1-α promoter knock-in cells; AID−/−, DT40 AID−/−.
bSequences that contained at least a 1-nt change, as described in Materials 
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including the loxP site inserted immediately upstream of the 
enhancer. Targeted integration effi     ciency of the enhancer 
deletion construct was  24% (not depicted). Clones were 
subsequently treated with Cre protein and seeded out as 
  described in Generation of IgL promoter..., and deletion of 
the puromycin selection cassette was verifi  ed by Southern 
blotting (Fig. 3 B).
Northern blotting demonstrated that deletion of the 
  enhancer in the context of the wild-type promoter (∆E cells) 
reduced transcription twofold compared with WT cells, 
whereas deletion in the context of the β-actin promoter 
(βA∆E cells) reduced transcription by only 15% compared 
with βA cells, with transcription levels remaining 2.6-fold 
higher than in WT cells (Fig. 1 C). These results indicate that 
the enhancer only contributes moderately to transcription in 
the DT40 IgL locus. In the E cells, IgL expression was unal-
tered compared with WT cells (Fig. 1 C), showing that syn-
onymous replacement of the enhancer had no measurable 
eff  ect on IgL transcription.
The IgL enhancer is dispensable for GCV/SHM
We analyzed the ∆E, βA∆E, and E cells for IgL GCV/SHM 
and included the same subcloning procedure as described in 
The β-actin promoter... to test the stability of GCV/SHM 
phenotypes. Sequencing results from two generations of ∆E 
cells indicated that GCV/SHM levels were reduced by al-
most fi  vefold compared with WT cells (Table I). IgM rever-
sion assays showed reductions of about four- and twofold 
relative to WT and E cells, respectively (two generations of 
cells analyzed; Fig. 2 A, Fig. 3 C, and Fig. S2 E). Both assays 
indicated that some GCV/SHM activity remained in the ab-
sence of the enhancer. In addition, much of the decrease in 
GCV/SHM observed in ∆E cells compared with E cells was 
likely caused by the twofold decrease in IgL transcription 
caused by deletion of the enhancer. In the βA∆E cells, IgL 
transcription was substantially stronger than in WT or L cells 
(Fig. 1 C); thus, eff  ects on GCV/SHM are unlikely to be re-
sults of reduced transcription. Analysis of three generations of 
βA∆E cells demonstrated that they were able to produce 
Figure 3.  Analyses of enhancer-deleted cells. (A) Stepwise schematic 
diagram of the generation of IgL enhancer-deleted cells. Components of 
the IgL locus are as detailed in Fig. 1. Relevant restriction enzyme sites and 
the constant region probe (solid bar) used in Southern and Northern blots 
are indicated, as are the puromycin resistance cassette (puroR; rectangle) 
and its fl  anking loxP sites (triangles). (B) Representative Southern blots 
for identifying targeted integrants of the enhancer deletion construct 
(BclI/HindIII digest, top) and verifying successful Cre-mediated deletion 
(BclI digest, bottom). WT, random integrants that show wild-type band 
patterns; REC, targeted recombinant clones. In both blots, the higher 
  molecular mass bands in each sample come from the unrearranged IgL allele 
(unrrng). The lower bands are derived from the rearranged allele (rrng; 
lanes 3 and 4, top), the targeted allele (T; lanes 1 and 2, top; lane 1, bottom), 
or the Cre-deleted allele (D; lanes 2–4, bottom). (C) Time course analysis of 
IgM+ cell accumulation in different cell types. The median of each cell type, 
including all generations of subclones, is plotted at various time points.JEM VOL. 203, December 25, 2006  2925
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some sIgM+ cells, confi  rming the fi  nding from ∆E cells that 
the enhancer is not essential for GCV/SHM. Nevertheless, 
the median was reduced by 30% compared with βA cells 
(P ≤ 0.0001; Fig. 2 A, Fig. 3 C, and Fig. S2 F). Interestingly, 
by IgM reversion assay, E cells also showed a  30% reduc-
tion in levels of GCV/SHM compared with WT cells (Fig. 
2 A), which was similar in magnitude to the reduction observed 
in βA∆E cells compared with βA cells. This suggests that the 
IgL locus manipulations that accompanied enhancer deletion 
cause a measurable reduction in GCV/SHM and that the 
drop in GCV/SHM activity seen in βA∆E cells compared 
with βA cells was the result of the manipulations and not the 
absence of the enhancer sequences. This was supported by 
sequencing analyses of two generations of βA∆E cells, as the 
GCV/SHM levels were indistinguishable from that observed 
in βA cells (Table I). Collectively, our results indicate that 
the IgL enhancer is not required for GCV/SHM of the locus 
and that when transcription is driven at high levels, the con-
tribution of the enhancer to GCV/SHM is quite modest.
D  I  S  C  U  S  S  I  O  N 
In this study, the roles of two cis-acting elements in GCV/
SHM of the chicken DT40 IgL locus were investigated: 
the promoter and the enhancer. Replacement of the endo-
genous IgL promoter with the inactive bacteriophage T7 
promoter led to complete abrogation of GCV/SHM, indi-
cating an essential role for an active promoter in chicken Ig 
gene   diversifi  cation. Two other non-Ig promoters were also 
tested for their ability to substitute functionally for the IgL 
promoter. Unexpectedly, the EF1-α promoter supported 
GCV/SHM poorly despite driving IgL expression at levels 
 1.5-fold higher than that obtained with the endogenous 
IgL promoter. Given the proposal that a positive correlation 
exists between transcription levels and Ig gene diversifi  cation 
frequencies (12, 19), the GCV/SHM defect in EF cells could 
be as much as sixfold compared with L and EF-L cells. To 
our knowledge, this is the fi  rst time a strong promoter has 
been shown to have a signifi  cant defect in supporting SHM 
or GCV of an endogenous Ig gene. These results indicate, in 
contrast to currently prevailing models, that there are roles 
of the promoter in GCV/SHM beyond driving high levels 
of transcription.
Although the β-actin promoter was able to substitute for 
the endogenous IgL promoter to support GCV/SHM, it did 
so at levels similar to those supported by the endogenous IgL 
promoter (L and EF-L cells), despite driving more than three-
fold higher steady-state IgL transcript levels than the endoge-
nous promoter. That a higher GCV/SHM activity was not 
observed in the βA cells could refl   ect saturating levels of 
transcription driven by the endogenous IgL promoter for 
GCV/SHM. Alternatively, the β-actin promoter, like the 
EF1-α promoter, could be suboptimal for recruitment of 
AID or other aspects of GCV/SHM, which in turn would 
suggest that the endogenous IgL promoter has features that 
render it particularly effi     cient in mediating GCV/SHM. 
A third possibility is that the positive correlation between 
transcription and diversifi  cation levels inferred from studies 
of transgenes and artifi  cial SHM substrates does not apply 
to the endogenous Ig loci. Our experiments only assessed 
steady-state mRNA levels, but because the transcribed region 
is   virtually identical in all of the cell lines examined in this 
  paper, the results are likely to refl  ect relative transcription 
rates as well.
Most previous analyses of the role of promoters in SHM 
have been performed using transgenes in mice and cell lines, 
and the ability of non-Ig promoters to support SHM has led 
to the proposal that endogenous Ig promoters are entirely 
  replaceable (12, 16, 18, 19, 34, 35). These results should be 
interpreted cautiously, because transgenes typically mutate at 
substantially lower frequencies than endogenous Ig genes and 
are subject to integration site eff  ects. In the two previous 
studies in which an endogenous Ig promoter was   manipulated 
(13, 15), mutation frequencies were reduced but so was 
transcription. In our study, targeted manipulation of the endo-
genous IgL promoter yielded loci with high-level transcrip-
tion, which revealed previously unappreciated roles of the 
promoter region in the targeting of GCV/SHM.
Cell line–based studies, as well as bacterial and in vitro 
  assays, have led to the model that transcription is important 
for generating single-stranded DNA suitable for AID deami-
nation (12, 36, 37), implying that stronger promoter activity 
translates into more AID substrates being available, thereby 
leading to higher levels of mutation. There is also evidence to 
indicate that AID interacts directly with RNA polymerases, 
supporting the idea that AID could traverse the transcribed 
region with the transcription elongation complexes (14, 38, 39). 
Though our results do not contradict the role of transcription 
in such models, they demonstrate that an active promoter is 
important for GCV/SHM for reasons beyond driving high 
levels of transcription. One possibility is that the EF1-α 
  promoter fails to recruit certain transcription factors to its 
transcription initiation or elongation complexes that are impor-
tant for AID recruitment or for locus interactions involved in 
GCV/SHM.
Our experiments also revealed that the targeted integra-
tion scheme used interfered with GCV/SHM. After targeted 
integration of the designated DNA elements and Cre-mediated 
deletion of the selection cassette, 59- and 80-bp regions 
  including the loxP site are left in the IgL locus immediately 
upstream of the promoter and in place of the enhancer with 
the respective targeting constructs (Fig. 1 A and Fig. 3 A). 
These insertions might interrupt DNA elements needed for 
optimal GCV/SHM. Alternatively, sequences within the in-
sertions or the targeted integration process itself could have 
interfered with GCV/SHM.
A recent study reported that deletion of the enhancer 
in the DT40 IgL locus leads to a 1,000-fold reduction in 
IgL  transcription (25). However, additional Southern blot 
analyses of the single enhancer-deleted clone generated by 
Conlon and Meyer indicated that Cre-mediated removal of 
the selection cassette integrated at the site of the deleted en-
hancer was unsuccessful (not depicted; Meyer, K.B., personal 2926  IG PROMOTER AND ENHANCER IN GCV/SHM | Yang et al.
communication), and thus those cells and that study are not 
informative as to the phenotype caused by enhancer deletion. 
The ability of our ∆E and βA∆E cells to perform some levels 
of GCV/SHM indicates that the enhancer is not necessary 
for IgL GCV/SHM. Nonetheless, GCV/SHM effi   ciencies 
are moderately compromised in both ∆E and βA∆E cells. 
  Although the reduction in GCV/SHM of ∆E cells could be 
caused by reduced transcription compared with WT cells, 
the small decrease in GCV/SHM seen in βA∆E cells relative 
to βA cells is likely caused by the targeted integration scheme. 
Overexpression of the E2A-encoded protein E47 stimulates 
GCV/SHM in DT40 cells (25), whereas deletion of the E2A 
gene substantially reduces GCV/SHM in DT40 (27), leading 
to the proposal that E2A proteins facilitate GCV/SHM 
through direct binding to the IgL enhancer (25, 27). Our 
data, however, suggest that the IgL enhancer, which contains 
six E2A binding motifs, is not the E2A-responsive element 
involved in the potentiation of IgL GCV/SHM.
Based on our fi  ndings, we favor the model that Ig loci are 
organized into higher order structures through interactions 
between multiple cis-acting elements, including the  promoter, 
thereby creating an interaction surface that is important for 
targeting of GCV/SHM. As none of the Ig elements mani-
pulated in this study led to signifi  cant changes in the GCV to 
SHM ratio or altered SHM patterns (χ2 analyses; Table I and 
not depicted), the eff  ects we observed are most likely medi-
ated at the level of recruitment of AID. Although deletion or 
alteration of one of the interacting elements would perturb 
targeting effi   ciency, it does not necessarily lead to the collapse 
of the entire structure. Further examination of the IgL locus 
will be important for identifying other DNA elements that 
contribute to GCV/SHM. It will be interesting to determine 
if any single IgL element is necessary for GCV/SHM, or if 
the targeting specifi  city of GCV/SHM is established through 
many interactions that in combination impose a high degree 
of specifi  city on Ig gene diversifi  cation processes.
MATERIALS AND METHODS
Constructs. Homology arms used in the promoter-exchange targeting 
construct were PCR-amplifi  ed from DT40 genomic DNA. A 3.5-kb left 
  homology arm (5LEFT1-5′-gatctatagcagcggccgcagaccctcaaacatcccttca-3′, 
3LEFT-5′-gccaggccttaattaagggacacgtg-3′) and a 1-kb right homology arm 
(CVLF1-5′-cagtaagcttaccatggcctgggctcctctcctcctg-3′, CLA2X-5′-gactctc-
gaggacagcacttacctggacagctg-3′) fl  anked the promoters of interest and a 
puromycin selection cassette. The bacteriophage T7 promoter was cloned 
by annealing two complementary oligos (T7BHT-5′-gatcttaattaaggatccta-
atacgactcactataggga-3′ and T7BHBN-5′-agcttccctatagtgagtcgtattaggatcctta-
attaa-3′), and the chicken β-actin promoter was derived as an NheI-HinfI 
fragment from the pLoxPuro plasmid (40). Two constructs carrying the 
  human EF1-α promoter were generated through PCR amplifi  cation of the 
pEBB plasmid (41): one included the region up to the end of the small fi  rst 
exon of the human EF1-α gene (5BAMEF-5′-cttgaaaggaggatccattggctccg-3′, 
EFHIN3-5′-aaccacacacgaagcttacctgtg-3′), whereas the other ended im-
mediately downstream of the transcription start site of the EF1-α promoter 
(5BAMEF, EFHINR2-5′-ccatggtaagctttgggatgttctggcggcaaacccgttg-3′). The 
fi  rst construct led to bypass of the leader exon during mRNA splicing, and 
the target-integrated clones derived with this construct were assayed for 
GCV/SHM by sequencing and not IgM reversion; the second construct 
preserved the original leader to V region splice pattern (not depicted). To 
generate the construct for reinserting the IgL promoter into its endogenous 
location, the right homology arm was rederived using a diff  erent primer 
set (VLP5BF-5′-gctgccacgggatcccgctgca-3′, CLA2X). The puromycin selec-
tion cassettes were fl  anked by loxP sites to allow removal by Cre recombi-
nase with the resulting single loxP site containing mutations that render it 
inactive (40).
The enhancer deletion construct contained homology arms 2.2 kb up-
stream and downstream of the enhancer fl  anking a Cre-removable puromy-
cin selection cassette. The arms were PCR-amplifi  ed from DT40 genomic 
DNA (upstream arm: CLEUF2-5′-ggcgcatacacacatattgg-3′, CLEUPR-5′-
gcctgctaattaattgccatgtc-3′; downstream arm: CLEDHF-5′-ccacgcataagcttg-
gccccac-3′, CLEDXR-5′-gaatatctcgagaggagac-3′). The targeting construct 
for reinsertion of the IgL enhancer contained a diff  erent downstream homol-
ogy arm (CLE-HF-5′-ctggcgacaaagcttcagcagagc-3′, CLEDXR).
Cell culture, transfection, and Cre-mediated deletion. All DT40 
clones were grown in RPMI 1640 (Invitrogen) supplemented with 10% 
heat-inactivated fetal bovine serum (Benchmark), 1% heat-inactivated 
chicken serum (Sigma-Aldrich), 2 mM l-glutamine (Invitrogen), 100 U/L 
penicillin (Invitrogen), and 100 μg/ml streptomycin (Invitrogen) at 41°C. 
The CL18 clone of DT40 cells and the AID−/− DT40 cells were gener-
ously provided by J.-M. Buerstedde (GSF-National Research Center for 
Environment and Health, Neuherberg, Germany) (2, 30). Transfections 
were performed by electroporating 107 cells with 25 μg linearized targeting 
vectors at 580 V and 25 μF in PBS. Transfected cells were seeded out at 
limited dilution in 0.5 μg/ml puromycin 10–14 h after electroporation, and 
stable transfectants were isolated 6–8 d later. Cre-mediated deletions were 
performed 14 d after transfection. 3 × 105 cells were treated with 6 μM 
his-Tat-NLS-Cre (HTNC; provided by F. Edenhofer, University of Bonn, 
Bonn, Germany) recombinant protein (42) for 1–6 h in 300 μl serum-free 
media. Cells were single-cell seeded after the incubation, and clones were 
identifi  ed 6–8 d later.
Southern and Northern blotting. To screen clones for targeted inte-
gration and successful Cre deletion, genomic DNA was purifi  ed, digested 
with restriction enzymes, separated on 0.8% agarose gels, transferred onto 
membranes (GeneScreen Plus; PerkinElmer), and blotted with random 
hexamer-labeled DNA probes (Roche) against the IgL constant region 
(CCLF1-5′-cccaccgtcaaaggaggagctg-3′ and CCLR2-5′-gacagtgacaggtagct-
gctggccatatac-3′) and puromycin region (HindIII-BamHI or HindIII-AccI 
fragments of pLoxPuro) (40). To analyze expression, RNA was extracted 
from various clones using RNA-Bee (Tel-Test, Inc.), separated on form-
aldehyde agarose gels, and transferred onto GeneScreen Plus membranes. 
Blots were hybridized with random hexamer-labeled probes against the IgL 
constant region and GAPDH (CHGAPDHF-5′-accagggctgccgtcctctc-3′ 
and CHGAPDHR-5′-ttctccatggtggtgaagac-3′).
IgM reversion assay. Clones were stained weekly with a PE–α-chicken 
IgM antibody (clone M-1; Southern Biotechnology Associates, Inc.) and 
analyzed by a fl  ow cytometer (FACScan; BD Biosciences).
Sequencing analysis. IgL and IgH variable regions were PCR amplifi  ed 
using high-fi  delity Pfu (Stratagene) or Phusion (New England Biolabs, Inc.) 
polymerases (IgL: CVLF1-5′-ccatggcctgggctcctctcctcctg-3′, CLA2-5′-gacag-
cacttacctggacagctg-3′; heavy chain: CVH1F1-5′-cgggagctccgtcagcgctctct-
gtcc-3′, CJH1R1-5′-ggggtacccggaggagacgatgacttcgg-3′) (43), TA-cloned 
(Invitrogen), and sequenced with the forward PCR primer or universal prim-
ers at the W.M. Keck Facility at the Yale University School of Medicine.
Sequences were aligned using CLUSTALW (http://align.genome.jp), 
and sequence variations in the IgL gene were categorized as long-track 
GCV, templated mutations, and nontemplated events. Long-track GCV 
events were those consisting of at least two nucleotide changes that were 
perfect matches to the same pseudoV (ψV) gene. Single nucleotide changes 
were scored as templated mutations when there was perfect identity between 
a ψV gene and the nucleotide change plus at least fi  ve nucleotides upstream JEM VOL. 203, December 25, 2006  2927
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and downstream of it. All other changes were classifi  ed as nontemplated 
events. Sequence diversifi  cation in IgH was not subcategorized, because the 
IgH ψV gene database is incomplete. Instead, the percentages of sequences 
that contained at least one nucleotide change relative to the germline se-
quence were calculated and used for comparisons.
Statistics. Two-sample t tests were used to determine the statistical signifi  -
cance of diff  erences in IgM reversion levels and mutation frequencies by 
  sequencing using Data Desk software (version 6.2; Data Description, Inc.). 
χ2 analyses were performed to determine if the distribution of GCV/SHM 
events in diff  erent cell types were statistically signifi  cant.
Online supplemental material. Fig. S1 is a Northern blot analysis of IgL 
expression in promoter-substituted cells. Fig. S2 is a time course analysis 
of IgM+ reversion in individual subclones of various promoter-  substituted 
cells. Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20061835/DC1.
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